Join the Brukinsa group to help and get support from people like you.
Brukinsa News
U.S. FDA Approves Tablet Formulation of BeOne’s Brukinsa for All Approved Indications
SAN CARLOS, Calif.--(BUSINESS WIRE) Jun 11, 2025 – BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug A...
BeiGene Announces FDA Accelerated Approval of Brukinsa for the Treatment of Relapsed or Refractory Follicular Lymphoma
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.-- Mar 07, 2024 (BUSINESS WIRE)-- BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food...
FDA Approves Label Update for Brukinsa (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
U.S. label update includes superior progression-free survival results from the Phase 3 ALPINE head-to-head trial of Brukinsa versus Imbruvica® (ibrutinib) in Relapsed or Refractory CLL ALPINE is the ...
Brukinsa (zanubrutinib) Approved in the U.S. for Chronic Lymphocytic Leukemia
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. – January 19, 2023 --(BUSINESS WIRE)-- BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the U.S....
U.S. FDA Grants Brukinsa (zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone Lymphoma
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE) September 15, 2021 – BeiGene Co.,Ltd (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative...
U.S. FDA Grants Brukinsa (zanubrutinib) Approval in Waldenström’s Macroglobulinemia
CAMBRIDGE, Mass. & BEIJING, September 01, 2021--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative...
FDA Approves Brukinsa (zanubrutinib) for the Treatment of Mantle Cell Lymphoma
CAMBRIDGE, Mass. and BEIJING, China, Nov. 14, 2019 (GLOBE NEWSWIRE) – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
Further information
Related condition support groups
Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma